EVP, CHIEF FINANCIAL OFFICER

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Institution	Shares	Value	Change
BlackRock	22,515,173	$570M	INCREASED
State Street	9,076,212	$230M	INCREASED
Pictet Asset Management Holding	1,983,198	$50M	DECREASED
Massachusetts Financial Services Co /MA	855,435	$22M	DECREASED
Principal Financial Group	789,196	$20M	INCREASED

Insider	Type	Shares	Value	Date
Mark C. Schneyer (EVP, CHIEF FINANCIAL OFFICER)	EXERCISE	14,292	$255K	2026-08-05
Mark C. Schneyer (EVP, CHIEF FINANCIAL OFFICER)	EXERCISE	5,849	$104K	2026-08-05
Mark C. Schneyer (EVP, CHIEF FINANCIAL OFFICER)	SELL	9,292	$273K	2026-08-05
Mark C. Schneyer (EVP, CHIEF FINANCIAL OFFICER)	SELL	5,000	$145K	2026-08-05
Mark C. Schneyer (EVP, CHIEF FINANCIAL OFFICER)	SELL	5,849	$170K	2026-08-05

Acadia Pharmaceuticals Inc. (ACAD) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades